Kamada (KMDA) Secures FDA Approval for In-House Rabies Virus Testing Lab

Kamada Ltd. (KMDA) received U.S. Food and Drug Administration approval on June 1, 2026 to establish an in-house laboratory for rabies virus neutralization testing. The authorization allows the company to perform critical assays internally, reducing reliance on external facilities. The move is expected to streamline quality control for its rabies immune globulin therapy, Kedrab, by shortening testing turnaround times and lowering operational costs. Kamada did not immediately disclose the timeline for the laboratory’s operational launch or potential financial impact. Shares of Kamada closed at $6.82 on May 30, ahead of the announcement.